Last reviewed · How we verify
DA-2803-R
DA-2803-R, marketed by Dong-A ST Co., Ltd., holds an established position in its therapeutic area despite the unknown mechanism of action. The drug's key strength lies in its current market presence, which is protected until 2028 by a key composition patent. The primary risk is the lack of understanding of its mechanism of action, which may limit further development and differentiation from potential competitors.
At a glance
| Generic name | DA-2803-R |
|---|---|
| Sponsor | Dong-A ST Co., Ltd. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DA-2803-R CI brief — competitive landscape report
- DA-2803-R updates RSS · CI watch RSS
- Dong-A ST Co., Ltd. portfolio CI